Go to content
UR Home

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?

URN to cite this document:
DOI to cite this document:
Trum, Maximilian ; Riechel, Johannes ; Wagner, Stefan
License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 11 Jan 2022 14:42


Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment strategy for heart failure with reduced ejection fraction (HFrEF) and-depending on the wistfully awaited results of two clinical trials (DELIVER and EMPEROR-Preserved)-may be the first drug class to improve cardiovascular outcomes in patients suffering from heart failure with preserved ejection fraction (HFpEF). ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons